Lexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Consensus Rating of “Buy” from Analysts

Lexeo Therapeutics, Inc. (NASDAQ:LXEO) has earned a consensus recommendation of “Buy” from the six research firms that are presently covering the company, Marketbeat reports. Five equities research analysts have rated the stock with a buy recommendation and one has issued a strong buy recommendation on the company. The average 12 month price target among brokers that have issued a report on the stock in the last year is $22.80.

Several research firms have recently commented on LXEO. HC Wainwright reissued a “buy” rating and issued a $23.00 price target on shares of Lexeo Therapeutics in a research report on Wednesday, March 26th. Royal Bank of Canada decreased their target price on shares of Lexeo Therapeutics from $24.00 to $20.00 and set an “outperform” rating for the company in a research report on Tuesday, March 25th. Chardan Capital reaffirmed a “buy” rating and set a $25.00 price target on shares of Lexeo Therapeutics in a research report on Tuesday, March 25th. Finally, Leerink Partners lowered their price objective on Lexeo Therapeutics from $19.00 to $18.00 and set an “outperform” rating for the company in a research report on Monday, March 24th.

Lexeo Therapeutics Trading Down 11.4 %

Shares of LXEO opened at $2.34 on Wednesday. Lexeo Therapeutics has a twelve month low of $2.27 and a twelve month high of $19.50. The company has a current ratio of 5.95, a quick ratio of 5.95 and a debt-to-equity ratio of 0.01. The company’s fifty day simple moving average is $3.82 and its 200-day simple moving average is $6.29. The company has a market cap of $77.68 million, a P/E ratio of -0.74 and a beta of 1.52.

Lexeo Therapeutics (NASDAQ:LXEO) last announced its quarterly earnings data on Monday, March 24th. The company reported ($0.78) earnings per share for the quarter, beating analysts’ consensus estimates of ($0.87) by $0.09. As a group, analysts expect that Lexeo Therapeutics will post -3.14 EPS for the current year.

Hedge Funds Weigh In On Lexeo Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the company. Frazier Life Sciences Management L.P. acquired a new position in shares of Lexeo Therapeutics during the third quarter worth about $11,307,000. Janus Henderson Group PLC grew its holdings in Lexeo Therapeutics by 18.9% during the 3rd quarter. Janus Henderson Group PLC now owns 3,763,195 shares of the company’s stock worth $33,997,000 after acquiring an additional 599,203 shares in the last quarter. Altium Capital Management LLC acquired a new position in Lexeo Therapeutics during the 4th quarter worth approximately $2,665,000. Point72 Asset Management L.P. increased its position in shares of Lexeo Therapeutics by 102.5% in the 4th quarter. Point72 Asset Management L.P. now owns 750,235 shares of the company’s stock valued at $4,937,000 after purchasing an additional 379,828 shares during the last quarter. Finally, Vestal Point Capital LP raised its holdings in shares of Lexeo Therapeutics by 41.2% in the 4th quarter. Vestal Point Capital LP now owns 1,200,000 shares of the company’s stock valued at $7,896,000 after purchasing an additional 350,000 shares in the last quarter. 60.67% of the stock is currently owned by hedge funds and other institutional investors.

About Lexeo Therapeutics

Lexeo Therapeutics, Inc operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene.